Just to reiterate, we understand that recent versions of the IP chapter include more than a dozen measures that would actually limit competition and might raise prices in markets for drugs including, as you mentioned, provisions that would extend patent terms beyond 20 years and that would lower the standards of attaining patents. So what effect would this have on Canadian patients and the medicare system?
On March 27th, 2014. See this statement in context.